Symptomatic therapy

Handbook of Multiple Sclerosis, Third Edition

Volumn , Issue , 2001, Pages 601-608

  Schapiro, Randall T ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0042951686     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (27)

1. Krupp LB, Alvarez LA, La Rocca NG, Scheinberg LC. Fatigue in multiple sclerosis. Arch Phys Med Rehabil 1988; 45:435-437.
2. Wolinsky JS, Narayana PA, Fenstermacher MJ. Proton magnetic spectroscopy in multiple sclerosis. Neurology 1990; 40:1764-1769.
3. Schapiro RS. Symptom Management in Multiple Sclerosis. 3rd ed. New York: Demos Publications, 1998, p 27.
4. Weinshenker BG, Penman M, Bass B, Ebers GC, Rice GPA. A double-blind, randomized crossover trial of pemoline in fatigue associated with multiple sclerosis. Neurology 1992; 42: 1468-1471.
5. United Kingdom Tizanidine Trial Group. A double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. Neurology 1994; 44(suppl 9):S70-S78.
6. Bass B, Weinshenker B, Rice GPA. Tizanidine versus baclofen in the treamtent of spasticity in patients with multiple sclerosis. Can J Neurol Sci 1988; 15:15-19.
7. Dunevsky A, Berel AB. Gabapentin for relief of spasticity associated with multiple sclerosis. Am J Phys Med Rehabil 1998; 77:451-454.
8. Calne DB. Drug treatment of spasticity and rigidity. Mod Trends Neurol 1975; 6:25-27.
9. Schapiro, RT. Symptom Management in Multiple Sclerosis, 3rd ed. New York: Demos Publications, 1998.
10. Penn RD, Savoy SM, Corcos D. Intrathecal baclofen for severe spinal spasticity. N Engl J Med 1989; 320:1517-1521.
11. Borg-Stein J, Fine Z, Mille RJ, Brin M. Botulinum toxin for the treatment of spasticity in multiple sclerosis. Am J Phys Med Rehabil 1993; 72:364-468.
12. Davis FA, Stefoski D, Rush J. Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol 1990; 27:186-192.
13. Fowler CJ, van Kerrebroeck PE, Nordenbo A, Van Poppel H. Treatment of lower urinary tract dysfunction in patients with multiple sclerosis. Committee of the European Study Group of SUDIMS. J Neurol Neurosurg Psychiatry 1992; 55:986-989.
14. Betts CD, D’Mellow MT, Fowler CJ. Urinary symptoms and neurological features of bladder dysfunction in multiple sclerosis. J Neurol Neurosurg Psychiatry 1993; 56:245-250.
15. Chao R, Clowers DE. Experience with intracavernosal tri-mixture for the management of nellurogenic erectile dysfunction. Arch Phys Med Rehabil 1994; 75:276-278.
16. Schapiro RT. Symptom Management in Multiple Sclerosis, 3rd ed. New York: Demos Publications, 1998.
17. Viera AJ, Clenney TC, Shernerberger DW, Grea FF. Newer pharmacologic alternatives for erectile dysfunction. Am Fam Physician 1999; 60(4):1159-1166.
18. Schapiro RT. Symptom Management in Multiple Sclerosis, 3rd ed. New York: Demos Publications, 1998.
19. Stenager E, Knudsen I, Jensen K. Acute and chronic pain syndromes in multiple sclerosis. Acta Neurol Scand 1991; 84:197-200.
20. Schapiro RT. Symptom Management in Multiple Sclerosis, 3rd ed. New York: Demos Publications, 1998.
21. Reder AT, Arnason BG. Trigeminal neuralgia in multiple sclerosis relieved by a prostaglandin E analogue. Neurology 1995; 45:1097-1100.
22. Rudick R, Schiffer RB, and Herndon RM. Drug treatment of multiple sclerosis. Semin Neurol 1987; 7:150-159.
23. Wasielowski PG, Burns JM, Kolwer WC. Pharmacologic treatment of tremor. Mov Disord 1998; 13 suppl 3:90-100.
24. Bozek CB, Kastrukoff LF, Wright JM, Perry TL, Larsen TA. A controlled trial of isoniazid therapy for action tremor in multiple sclerosis. Neurology 1987; 234:36-39.
25. Rice GP, Lesaux, J, Vandenoort P, Maceuar L, Ebers GC. Ondansetron, a 5-HT3 antagonist, improves cerebellar tremor. J Neurol Neurosurg Psychiatry 1997; 62:282-284.
26. Trouillas P, Xie J, Adeleine P. Treatment of cerebellar ataxia with buspirone. Lancet 1996; 348:759.
27. Beck RW, Cleary PA, Angerson PAC Jr. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med 1992; 326:581-588.